Petter Bjornstad

Petter Bjornstad

Auto-generated profile, based on publicly available information

Petter Bjornstad

Department of Medicine, Division of Endocrinology, Metabolism and Nutrition, University of Washington School of Medicine, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2014 in Gerontology
Verified
Journal Article
Closed access
PDF file
MKMegan M. Kelsey
Megan M. Kelsey
AZAlysia Zaepfel
Alysia Zaepfel
PBPetter Bjornstad
Petter Bjornstad
KNKristen J. Nadeau
Kristen J. Nadeau
The severity and frequency of childhood obesity has increased significantly over the past three to four decades. The health effects of increased body mass index as a child may significantly impact obese youth as they age. However, many of the long-term outcomes of childhood obesity have yet to be studied. This article examines the currently available longitudinal data evaluating the effects of childhood obesity on adult outcomes. Consequences of obesity include an increased risk of developing the metabolic syndrome, cardiovascular disease, type 2 diabetes and its associated retinal and renal complications, nonalcoholic fatty liver disease, obstructive sleep apnea, polycystic ovarian syndrome, infertility, asthma, orthopedic complications, psychiatric disease, and increased rates of cancer, among others. These disorders can start as early as childhood, and such early onset increases the likelihood of early morbidity and mortality. Being obese as a child also increases the likelihood of being obese as an adult, and obesity in adulthood also leads to obesity-related complications. This review outlines the evidence for childhood obesity as a predictor of adult obesity and obesity-related disorders, thereby emphasizing the importance of early intervention to prevent the onset of obesity in childhood.

17 October 2018 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
PBPetter Bjornstad
Petter Bjornstad
RERobert H. Eckel
Robert H. Eckel

31 October 2022 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
PBPetter Bjornstad
Petter Bjornstad
LCLily C. Chao
Lily C. Chao
MCMelanie Cree-Green
Melanie Cree-Green
ADAllison B. Dart
Allison B. Dart
MKMalcolm King
Malcolm King
RNRobert G. Nelson
Robert G. Nelson

7 June 2015 in Diabetologia
Verified
Journal Article
Open access
PDF file
PBPetter Bjornstad
Petter Bjornstad
MLMiguel A. Lanaspa
Miguel A. Lanaspa
TITakuji Ishimoto
Takuji Ishimoto
TKTomoki Kosugi
Tomoki Kosugi
SKShinji Kume
Shinji Kume
TNTakahiko Nakagawa
Takahiko Nakagawa
Clinical studies have reported associations between serum uric acid levels and the development of diabetic nephropathy, but the underlying mechanisms remain elusive. There is evidence from animal studies that blocking uric acid production protects the kidney from tubulointerstitial injury, which may suggest a causal role for uric acid in the development of diabetic tubular injury. In turn, when fructose, which is endogenously produced in diabetes via the polyol pathway, is metabolised, uric acid is generated from a side-chain reaction driven by ATP depletion and purine nucleotide turnover. For this reason, uric acid derived from endogenous fructose could cause tubulointerstitial injury in diabetes. Accordingly, our research group recently demonstrated that blocking fructose metabolism in a diabetic mouse model mitigated the development of tubulointerstitial injury by lowering tubular uric acid production. In this review we discuss the relationship between uric acid and fructose as a novel mechanism for the development of diabetic tubular injury.

1 August 2014 in Current Opinion in Endocrinology, Diabetes and Obesity
Verified
Journal Article
Closed access
PBPetter Bjornstad
Petter Bjornstad
DCDavid Cherney
David Cherney
DMDavid M. Maahs
David M. Maahs
Purpose of review Despite improvements in glycemic and blood pressure control in patients with type 1 diabetes, diabetic nephropathy remains the most common cause of chronic kidney disease worldwide. A major challenge in preventing diabetic nephropathy is the inability to identify high-risk patients at an early stage, emphasizing the importance of discovering new therapeutic targets and implementation of clinical trials to reduce diabetic nephropathy risk. Recent findings Limitations of managing patients with diabetic nephropathy with renin–angiotensin–aldosterone system blockade have been identified in recent clinical trials, including the failure of primary prevention studies in T1D and the demonstration of harm with dual renin–angiotensin–aldosterone system blockade. Fortunately, several new targets, including serum uric acid, insulin sensitivity, vasopressin, and sodium-glucose cotransporter-2 inhibition, are promising in the prevention and treatment of diabetic nephropathy. Summary Diabetic nephropathy is characterized by a long clinically silent period without signs or symptoms of disease. There is an urgent need for improved methods of detecting early mediators of renal injury, to ultimately prevent the initiation and progression of diabetic nephropathy. In this review, we will focus on early diabetic nephropathy and summarize potential new therapeutic targets.

9 April 2019 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
PBPetter Bjornstad
Petter Bjornstad
LLLori Laffel
Lori Laffel
JLJane Lynch
Jane Lynch
LGLaure El Ghormli
Laure El Ghormli
RWRuth S. Weinstock
Ruth S. Weinstock
FGfor the TODAY Study Group
for the TODAY Study Group
OBJECTIVE Elevated serum uric acid (SUA) is increasingly recognized as a risk factor for kidney disease in adults with diabetes, but data in youth are limited. We hypothesized that elevated SUA predicts development of elevated urinary albumin excretion (UAE) and hypertension over time in teens with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Serum creatinine, cystatin C, SUA, and the urine albumin-to-creatinine ratio (UACR) were assessed in 539 obese youth, ages 12–17 years, with T2D duration <2 years at baseline in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study. Estimated glomerular filtration rate (eGFR) was calculated using creatinine and cystatin C. Hypertension was defined as systolic or diastolic blood pressure ≥130/80 mmHg and elevated UAE as UACR ≥30 mg/g. Cox proportional hazards models evaluated the relationship between SUA and outcome variables longitudinally over an average follow-up of 5.7 years, adjusting for age, sex, race/ethnicity, BMI, HbA1c, eGFR, ACE inhibitor/angiotensin receptor blocker use, and TODAY treatment group assignment. RESULTS At baseline, hyperuricemia (≥6.8 mg/dL) was present in 25.6% of participants, hypertension in 18.7%, and elevated UAE in 6.1%. During follow-up of up to 7 years, hypertension developed in 37.4% and UAE in 18.0%. Higher baseline SUA increased the risk of incident hypertension (hazard ratio [HR] 1.19, 95% CI 1.03–1.38, per 1 mg/dL increase in SUA) and elevated UAE (HR 1.24, 95% CI 1.03–1.48) in adjusted models. CONCLUSIONS Hyperuricemia was common in youth with T2D. Higher baseline SUA independently increased the risk for onset of hypertension and elevated UAE. Research is needed to determine whether SUA-lowering therapies can impede development of diabetic kidney disease and hypertension in T2D youth.